|
|
Glioblastomas
with an oligodendroglial component: a pathological and molecular study
He
J, Mokhtari K, Sanson M, Marie Y, Kujas M, Huguet S, Leuraud P,
Capelle L, Delattre JY, Poirier J, Hoang-Xuan K
Biologie
des Interactions Neurone-Glie, INSERM U495 et Universite P. et M.
Curie, Paris, France.
Glioblastoma
(GBM) is considered by the WHO classification to represent the most
malignant grade of the astrocytic tumors.
However,
a subset of GBM includes recognizable areas with oligodendroglial
features, suggesting that some GBM may also have an oligodendroglial
origin.
The
aim of this study was to analyze the molecular profile of GBM
associated with an oligodendroglial component (GBMO).
We
analyzed a series of 25 GBMO.
Loss
of heterozygosity (LOH) on 1p and 19q, known as common markers of
oligodendroglial tumors, were observed in 40% and 60% of cases,
respectively; 72% of the tumors displayed one or both of these
markers.
All
but 4 tumors (84%) showed alterations known to be preferentially
involved in the progression of astrocytic tumors to GBM, such as EGFR
amplification (44%), P16 deletion (48%), LOH on 10q (64%), PTEN (20%),
and TP53 (24%) mutations.
Therefore,
GBMO displayed all the genetic aberrations found in
"standard" GBM with a comparable incidence, but differed
from GBM by having a higher rate of LOH on 1p and 19q.
These
results suggest that GBMO might represent a subgroup of tumors of
oligodendroglial origin that is distinct from the "standard"
GBM in terms of tumorigenesis pathway.
PMID: 11556543 [PubMed - indexed for MEDLINE]
|
